jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
Published 7 years ago • 152 plays • Length 1:28
Download video MP4
Download video MP3
Similar videos
-
1:06
jason luke, md: the impact of braf/mek inhibitors in melanoma
-
1:11
jeffrey weber, md, phd: the impact of moderate level of disease burden
-
1:46
jeffrey weber, md, phd explains the importance of testing for nras as compared with a braf biomarker
-
7:23
melanoma: braf/mek-inhibitors as adjuvant therapy
-
1:23
dr. jeffrey weber on the keys to targeted treatments
-
2:34
jeffrey weber, md, phd explains the importance of administering ipilimumab with a pd-l1 inhibitor
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
1:36
dr. weber on combination strategies for braf-mutant melanoma
-
1:26
jeffrey weber, md, phd provides interpretation of the nemo trial results
-
1:46
dr. weber on dabrafenib/trametinib approval for melanoma
-
8:40
melanoma: braf/mek targeted therapy
-
1:44
dr. jeffrey weber on optimal therapy sequences in advanced melanoma
-
1:27
dr. weber on side effects of dabrafenib/trametinib in melanoma
-
2:26
jeffrey weber, md, phd explains the long term data from keynote-001 study in advanced melanoma
-
1:08
dr. weber on dabrafenib/trametinib versus vemurafenib/cobimetinib in melanoma
-
1:54
jeffrey weber, md, phd, discusses the efficacy of checkpoint inhibitors and immunotherapy
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
6:05
duration of dual braf-mek inhibition
-
1:44
jeffrey weber, md, phd: predicting durable responses to targeted therapy
Clip.africa.com - Privacy-policy